List of Excipients in Branded Drug ACTIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cephalon LLC	ACTIQ	fentanyl citrate	63459-502	ANHYDROUS CITRIC ACID
Cephalon LLC	ACTIQ	fentanyl citrate	63459-502	DEXTRATES
Cephalon LLC	ACTIQ	fentanyl citrate	63459-502	MAGNESIUM STEARATE
Cephalon LLC	ACTIQ	fentanyl citrate	63459-502	MODIFIED CORN STARCH
Cephalon LLC	ACTIQ	fentanyl citrate	63459-502	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Cephalon LLC	ACTIQ	fentanyl citrate	63459-502	SUCROSE

ACTIQ Excipient Strategy and Commercial Opportunities in Fentanyl Oral Transmucosal Products

Last updated: August 21, 2026

ACTIQ is an immediate-release oral transmucosal fentanyl citrate lozenge for breakthrough cancer pain in opioid-tolerant patients. Its excipient system is simple: dextrose, confectioner's sugar, citric acid, dibasic sodium phosphate, artificial berry flavor, and magnesium stearate. The primary commercial opportunities are in sugar-free reformulation, taste and mucosal tolerability, rapid drug release, manufacturability, and differentiated abuse-risk controls. Regulatory constraints are substantial because fentanyl is a Schedule II opioid and ACTIQ is subject to specialized FDA controls for transmucosal immediate-release fentanyl products. [1]

What excipients are used in ACTIQ?

ACTIQ uses a sugar-based lozenge matrix designed to dissolve in the buccal cavity while the patient moves the dosage form against the inside of the cheek.

Component	Function in ACTIQ
Fentanyl citrate	Active pharmaceutical ingredient
Dextrose	Bulk diluent and sweetener
Confectioner's sugar	Diluent, sweetener, mouthfeel modifier
Citric acid	Flavor and pH adjustment
Dibasic sodium phosphate	Buffering agent
Artificial berry flavor	Taste masking and product identity
Magnesium stearate	Lubricant for manufacture

ACTIQ is available in 200, 400, 600, 800, 1,200, and 1,600 microgram strengths. The dosage form includes an oral transmucosal lozenge attached to a handle. Patients are instructed to move the unit along the inside of the cheeks and not chew, suck, or swallow it whole. [1]

The excipient system has four commercial design objectives:

1. Create a palatable product despite fentanyl's bitter taste.
2. Produce controlled dissolution during buccal administration.
3. Maintain dose uniformity across microgram-strength units.
4. Support high-volume manufacturing of a mechanically robust lozenge.

How does the ACTIQ excipient system support fentanyl absorption?

ACTIQ combines transmucosal and gastrointestinal absorption. Approximately 25% of the total fentanyl dose is absorbed through the buccal mucosa, while the remaining portion is swallowed and absorbed through the gastrointestinal tract. The absolute bioavailability is approximately 50%, with peak plasma concentrations generally occurring within 20 to 40 minutes. [1]

The formulation therefore does not function as a purely buccal delivery system. Dissolution rate, saliva production, swallowing behavior, contact with the buccal mucosa, and the patient's administration technique all affect exposure.

Role of sugars and tablet structure

Dextrose and confectioner's sugar provide:

• High solubility in saliva.
• Sweetness that offsets fentanyl bitterness.
• A familiar lozenge texture.
• Sufficient mass for handling a microgram-dose drug.
• A low-cost, widely available excipient platform.

The sugar base also creates a limitation. Patients with diabetes, dental disease, xerostomia, or repeated exposure to sucrose-containing products may prefer a sugar-free product. A reformulation would need to preserve dissolution, taste, mechanical strength, and fentanyl exposure.

Role of the acid-buffer system

Citric acid and dibasic sodium phosphate create a buffered flavor and dissolution environment. The system can influence:

• Local pH at the mucosal surface.
• Fentanyl citrate dissolution.
• Salivary solubility.
• Taste perception.
• Chemical stability.
• Buccal irritation.

A pH shift could improve release but also change tolerability or systemic exposure. Any alternative buffer would require comparative pharmaceutical equivalence and pharmacokinetic assessment.

What formulation patents protect ACTIQ?

ACTIQ's original commercial protection was based on the drug product, delivery concept, regulatory exclusivity, and historical patent rights associated with oral transmucosal fentanyl. The core composition is no longer a strong standalone barrier because the product has been marketed for more than two decades and its basic excipients are conventional.

The commercially relevant IP categories are:

IP category	Strategic relevance
Oral transmucosal fentanyl composition	Historical protection; limited value after expiration
Lozenge and handle configuration	May protect device presentation or manufacturing details
Rapid-release oral transmucosal delivery	Potentially relevant to differentiated products
Taste-masking formulation	Potentially useful for reformulated products
Abuse-deterrent or tamper-resistant design	Potential future product differentiation
Manufacturing process	Can protect content uniformity and mechanical properties
Method-of-use claims	Limited value where the indication is established and generic labeling is possible

The FDA Orange Book remains the controlling source for current listed patents, exclusivity, and reference-product information. ACTIQ's commercial opportunity is unlikely to depend on reasserting protection over the original sugar-based formulation. New protection would more plausibly arise from a materially different formulation, delivery system, abuse-deterrent architecture, or manufacturing process. [2]

When does ACTIQ lose exclusivity and what is the generic entry risk?

ACTIQ's original FDA approval occurred in 1998 under NDA 20-747. Its regulatory exclusivity period has expired. The key competitive issue is therefore not basic approval exclusivity but the ability of an applicant to demonstrate pharmaceutical equivalence, bioequivalence, quality, and regulatory compliance for a highly potent transmucosal opioid. [1, 2]

Paragraph IV challenges

A generic applicant could challenge any unexpired Orange Book patent through an abbreviated new drug application and Paragraph IV certification. The most likely targets would be:

• Any remaining formulation patent.
• A device or handle patent.
• A manufacturing patent.
• A method-of-use patent listed against the reference product.

For ACTIQ, a Paragraph IV challenge would have less commercial force if no unexpired, commercially material patents remain listed. The applicant's main burden would then be technical and regulatory: demonstrating equivalent delivery from a lozenge with the same route, dosage form, strength, and release characteristics.

Generic launch scenarios

Scenario	Commercial effect
Exact or near-exact sugar-based generic	Highest probability of price competition
Sugar-free generic	Differentiated niche, but requires formulation and bridging work
Alternative flavor generic	Limited differentiation unless taste performance improves materially
Buccal film or tablet	More likely 505(b)(2) than a conventional ANDA if not pharmaceutically equivalent
Abuse-deterrent transmucosal product	Potential premium product, but clinical and regulatory burden is higher
Hospital or specialty-distributor product	May compete on supply reliability and contract pricing

The risk of generic entry is high at the product level because the active ingredient, indication, route, and dosage strengths are established. The remaining barriers are controlled-substance handling, fentanyl manufacturing, dose uniformity, diversion controls, and the need to manage opioid-related regulatory scrutiny.

What excipient strategies could differentiate an ACTIQ successor?

1. Sugar-free formulation

Replacing dextrose and confectioner's sugar is the clearest excipient opportunity. Candidate platforms include:

• Mannitol.
• Xylitol.
• Sorbitol.
• Isomalt.
• Maltitol.
• Sucralose or acesulfame potassium for high-intensity sweetness.
• Polyols combined with compressible fillers.

The formulation must avoid excessive cooling, laxation, hygroscopicity, or crystallization. Xylitol can provide sweetness and a cooling sensation, but the cooling effect may alter perceived potency or reduce flavor acceptability. Sorbitol is highly water-soluble but may increase hygroscopicity. Mannitol has favorable mouthfeel but can produce a less sweet product and may require a co-sweetener.

A sugar-free product could target patients with diabetes, dental concerns, or preference for lower-sugar dosage forms. The commercial value would be highest if the product also improves taste, dissolution consistency, and patient adherence.

2. Taste masking

Fentanyl is potent at microgram doses, but bitterness remains a product-quality concern. Taste-masking options include:

• Ion-exchange resin complexes.
• Polymer coating.
• Cyclodextrin complexes.
• Lipid-based taste barriers.
• Encapsulated flavor systems.
• Sweetener and acidulant optimization.

A taste-masking system must release fentanyl rapidly after buccal contact. Excessive coating could reduce transmucosal absorption or delay onset. The product must also avoid increasing the amount of fentanyl retained in the mouth or creating a more attractive form for misuse.

3. Mucosal tolerability

Potential excipient development can focus on reducing irritation and improving wetting. Candidate technologies include:

• Low-irritancy buffer systems.
• Mucoadhesive polymers.
• Saliva-activated disintegration agents.
• Humectants.
• Controlled-pH microenvironments.

Mucoadhesion has a narrow design window. Strong adhesion may improve contact time, but it can also increase local fentanyl exposure and make the dosage form difficult to remove. A weakly adhesive, rapidly dissolving matrix may offer a better balance for a high-potency opioid.

4. Mechanical robustness and dose uniformity

Because ACTIQ contains very low quantities of fentanyl relative to the total dosage form, manufacturing controls are critical. Excipient systems should support:

• Content uniformity.
• Low segregation risk.
• Consistent compression.
• Resistance to chipping.
• Stable moisture content.
• Reproducible dissolution.
• Reliable attachment to the handle.

Co-processed excipients could improve flow and compressibility, but their use would need to be evaluated against powder segregation and fentanyl distribution. A platform that reduces manufacturing deviations could have greater value than a minor flavor improvement.

What regulatory pathway applies to ACTIQ reformulation?

A product that matches ACTIQ in active ingredient, dosage form, route, strength, and performance may be eligible for an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A materially different product may require a 505(b)(2) application. [3]

ANDA considerations

An ANDA strategy generally favors:

• The same fentanyl citrate active ingredient.
• The same dosage form.
• The same route of administration.
• Equivalent strengths.
• Comparable inactive ingredient functionality.
• Demonstrated bioequivalence.
• Product-specific labeling and controlled-substance controls.

A change from sugar-based to sugar-free excipients could be possible within an ANDA only if the formulation remains pharmaceutically equivalent and the inactive ingredients are acceptable for the route and dosage form. A major change in release behavior, device design, or mucosal delivery could move the product toward 505(b)(2).

505(b)(2) opportunities

A 505(b)(2) product could support:

• Sugar-free delivery.
• New mucoadhesive technology.
• A buccal film.
• A sublingual tablet.
• A novel flavor or sensory profile.
• Reduced-risk packaging.
• An abuse-deterrent design.
• A modified release profile.

The applicant would need to establish a clinically meaningful benefit or a regulatory basis for relying partly on ACTIQ or other published data. The commercial advantage must justify the larger development program and potentially longer review path.

What FDA controls apply to ACTIQ and transmucosal fentanyl?

ACTIQ is indicated only for opioid-tolerant adults with breakthrough cancer pain. It is not appropriate for opioid-naive patients or for routine acute pain. The product carries boxed warnings relating to life-threatening respiratory depression, medication errors, addiction, abuse, misuse, overdose, and accidental exposure. [1]

The product is subject to controlled-substance requirements and specialized risk-management obligations applicable to transmucosal immediate-release fentanyl products. FDA has historically required measures addressing prescriber education, pharmacy controls, patient counseling, and safe use. [4]

These controls affect commercial planning in four areas:

1. Distribution: Specialty and controlled-substance distribution capabilities are necessary.
2. Market access: Payers may impose prior authorization and opioid-specific utilization controls.
3. Promotion: Label-consistent promotion is tightly constrained.
4. Patient support: Enrollment, counseling, and safe-use systems can increase operating costs.

An excipient change that improves taste or convenience does not remove these obligations.

How strong is the ACTIQ patent estate?

The original ACTIQ composition has limited remaining patent strength because the product is mature and its excipients are conventional. A new formulation could create a stronger estate if the claims cover a specific combination that produces measurable advantages.

Potentially defensible claim areas

• A defined sugar-free excipient ratio.
• A specific dissolution profile in simulated saliva.
• A taste-masking system that preserves buccal exposure.
• A moisture-controlled manufacturing process.
• A fentanyl content-uniformity process.
• A mechanically integrated lozenge-handle system.
• Packaging that limits accidental exposure or diversion.
• A delivery system with demonstrated abuse-deterrent properties.

Broad claims covering "fentanyl with a sweetener" or "a transmucosal lozenge" would face substantial validity and obviousness risk. Narrow claims tied to analytical performance, process controls, or clinically demonstrated tolerability would be more commercially credible.

Which companies are challenging or competing with ACTIQ?

Competition comes from multiple product categories rather than a single direct substitute.

Competitor category	Examples or relevance
Generic oral transmucosal fentanyl	Direct price competition with ACTIQ
Fentanyl buccal tablets	Alternative transmucosal delivery
Fentanyl sublingual tablets	Compete on convenience and onset
Fentanyl buccal films	Compete on portability and dosage-form profile
Oral opioids	Lower-cost substitutes in selected patients
Nonopioid cancer-pain therapies	Limit long-term opioid use in some treatment plans
Specialty distributors	Compete through supply reliability and access controls

Direct competition depends on FDA-approved indications. Transmucosal fentanyl products are not automatically interchangeable because differences in dosage form, absorption, strength, and labeled use can affect substitution decisions.

What commercial opportunities exist for ACTIQ excipients?

The best opportunities are platform-based rather than single-ingredient sales.

Excipient supplier opportunities

Suppliers can pursue:

• Direct-compression sugar-free bases.
• Low-moisture polyol systems.
• Co-processed fillers for fentanyl content uniformity.
• High-intensity sweetener blends.
• Pharmaceutical-grade berry flavor systems.
• Rapid-dissolution binders.
• Low-irritancy buffer systems.
• Taste-masking excipients compatible with buccal delivery.
• Excipient packages supported by route-specific safety data.

The strongest commercial proposition would combine formulation performance with regulatory documentation, including compendial status, impurity controls, residual solvent data, elemental impurity data, nitrosamine risk assessment, and route-specific toxicology.

Revenue exposure

ACTIQ-related revenue is exposed to:

• Generic price erosion.
• Controlled-substance quota and supply restrictions.
• Payer preference for lower-cost alternatives.
• Declining use of transmucosal fentanyl.
• Opioid stewardship policies.
• Product liability and compliance costs.
• Manufacturing interruptions.

A sugar-free or improved-taste successor could protect revenue only if it earns formulary, prescriber, or patient preference. Excipient differentiation alone is unlikely to support a substantial premium without evidence of better adherence, reduced discontinuation, improved tolerability, or superior administration performance.

How does ACTIQ compare with newer transmucosal fentanyl products?

Attribute	ACTIQ	Buccal film or tablet successor
Dosage form	Lozenge on handle	Film, tablet, or other compact system
Main excipient challenge	Sugar base, taste, dissolution	Adhesion, rapid wetting, dose uniformity
Patient handling	Requires controlled movement in cheek	May be simpler to place and retain
Manufacturing	Compression and handle integration	Film casting, coating, or specialized compression
IP opportunity	Limited for basic composition	Greater opportunity around delivery architecture
Regulatory burden	Established reference product	Potentially higher if formulation differs materially
Abuse-risk profile	Established opioid controls	Requires separate assessment

ACTIQ retains value as a reference product because its clinical use, dosing strengths, and administration instructions are established. A newer product would need a clear advantage in handling, tolerability, sugar content, supply reliability, or risk control.

Key Takeaways

• ACTIQ uses a conventional sugar-based excipient system: dextrose, confectioner's sugar, citric acid, dibasic sodium phosphate, artificial berry flavor, and magnesium stearate.
• The formulation supports rapid dissolution and partial buccal absorption but relies on patient administration technique.
• The original excipient composition offers limited new patent value.
• The strongest reformulation opportunity is a sugar-free, rapidly dissolving, taste-masked lozenge.
• Mucoadhesion and pH optimization may improve performance but can increase local exposure and regulatory complexity.
• Generic entry risk is high because ACTIQ is a mature product with expired regulatory exclusivity.
• Controlled-substance controls, fentanyl manufacturing, dose uniformity, and FDA risk-management requirements remain meaningful commercial barriers.
• Excipient suppliers have the best opportunity in complete formulation platforms supported by route-specific regulatory data.
• A differentiated product would likely require an ANDA-compatible formulation or a 505(b)(2) strategy supported by measurable clinical or pharmaceutical advantages.

FAQs

Can ACTIQ be reformulated without changing the FDA approval pathway?

A limited excipient change may remain compatible with an ANDA if the product retains pharmaceutical equivalence and bioequivalence. A material change in delivery, release, or device architecture may require a 505(b)(2) application.

What is the best sugar substitute for an ACTIQ-like lozenge?

Mannitol, xylitol, sorbitol, isomalt, and maltitol are leading candidates. The best choice depends on dissolution, cooling effect, hygroscopicity, compressibility, taste, and gastrointestinal tolerability.

Can a taste-masked fentanyl lozenge obtain new patent protection?

Yes, if the formulation has novel and non-obvious features supported by measurable performance, such as improved taste without reduced buccal absorption or a defined release profile.

Would a buccal film be automatically substitutable for ACTIQ?

No. A buccal film would have a different dosage form and may have different absorption, administration, labeling, and substitution characteristics. It could require a separate regulatory application.

Why is fentanyl content uniformity especially important in ACTIQ products?

Fentanyl is active at microgram quantities. Small manufacturing deviations can produce clinically meaningful dose differences, making powder blending, segregation control, sampling, and analytical validation central to product quality.

References

1. U.S. Food and Drug Administration. (2023). ACTIQ (fentanyl citrate) oral transmucosal lozenge prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Stability of drug substances and drug products. FDA.

4. U.S. Food and Drug Administration. (2020). Transmucosal immediate-release fentanyl products risk evaluation and mitigation strategy. FDA.